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Clonal hematopoiesis in patients with anti-neutrophil
cytoplasmic antibody-associated vasculitis 
Clonal hematopoiesis of indeterminate potential
(CHIP) – defined by the presence of a somatic hematolog-
ic cancer-associated gene mutation with a variant allele
frequency of ≥2% – occurs in the peripheral blood of at
least 10% of individuals older than 60 years of age with-
out any history of a hematologic disorder.1,2 Mutations
mainly affect epigenetic regulators of transcription
DNMT3A, TET2, and ASXL1, leading to a competitive
advantage of mutated hematopoietic stem cells with a
subsequent differentiation bias toward the myeloid com-
partment.3,4 The frequency of CHIP increases with age
and associates with higher risk of developing hematolog-
ic malignancies and cardiovascular diseases, leading to
increased overall mortality.5 
Using a mouse model with Tet2-deficient macrophages,
it was shown that atherosclerosis and coronary heart dis-
ease are driven by CHIP via an altered inflammasome
function, leading to increased levels of pro-inflammatory
cytokines.6 Our group recently detected a correlation
between DNMT3A mutations and chronic graft-versus-
host disease, providing further evidence of an important
role of CHIP in chronic inflammatory reactions.7
However, little is known about the role of CHIP in
autoimmune diseases. A study in 56 patients with
rheumatoid arthritis showed no correlation of CHIP with
disease activity.8 Anti-neutrophil cytoplasmic antibody
(ANCA)-associated autoimmune vasculitides (AAV) com-
prise a variety of necrotizing vasculitides, including gran-
ulomatosis with polyangiitis and microscopic polyangi-
itis, and are characterized by severe small vessel inflam-
mation, potentially affecting every organ system. ANCA
are directed against the autoantigens myeloperoxidase
(MPO) and proteinase 3 (PR3). Upon binding to their cell-
surface-expressed antigens, ANCA IgG provoke uncon-
trolled activation of neutrophils and monocytes, leading
to endothelial damage and end-organ failure. In most
individuals, the highest mutation burden of CHIP can be
found in myeloid cells,4 which are the only autoantigen-
expressing primary responder cells in AAV. Furthermore,
TET2 and DNMT3A play a central role in gene silencing
by regulating DNA methylation. In fact, defective gene
silencing in myeloid cells from AAV patients has been
reported. This dysregulated process included the ANCA
autoantigens and correlated with relapse risk.9-11 
In summary, recent data support the idea of potential
links, regarding pathogenesis and clinical outcomes,
between CHIP and autoimmune diseases/inflammatory
conditions. We therefore characterized CHIP in a large
cohort of patients with AAV, examining prevalence,
dynamic changes over time, organ manifestations, ANCA
antigen silencing, and ANCA-induced in vitro activation.
We collected peripheral blood samples from patients
with AAV, seen at the Charité/HELIOS nephrology out-
patient departments and wards (Berlin, Germany,
between April 2005 and October 2018. The patients’
demographic and clinical data were extracted from their
medical records. All patients gave their written informed
consent to inclusion in the study, which was conducted
in accordance with the Declaration of Helsinki. Ethical
approval was obtained from the local ethics committees.
Whole-blood DNA was screened for CHIP using a cus-
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Figure 1. Sequencing analysis. (A) Spectrum of somatic gene mutations found in our cohort of 112 patients with ANCA-associated autoimmune vasculitis (AAV).
Genes marked with an asterisk are only covered by the custom panel (Online Supplementary Methods). (B) Prevalence of clonal hematopoiesis of indeterminate
potential (CHIP) according to age groups. Patients with a single mutation are represented in light blue, patients with multiple mutations in dark blue. (C)
Comparison of CHIP prevalence in the AAV cohort with prevalences in previously described cohorts. Error bars depict the 95% confidence intervals. (D)
Longitudinal quantification of variant allele frequencies (VAF) in selected patients. Only patients with a relevant increase or decrease of VAF over time are shown.
The therapy regimens administered are depicted as colored bars on the x-axis. Relapse is represented by triangles. UPN: unique patient number; AZA: azathio-




tomized version of the Illumina TruSight Myeloid
Sequencing Panel (Online Supplementary Table S1) on a
NextSeq sequencer. Sequencing analysis was performed
using an Illumina BaseSpace platform sequencing HUB.
Only nonsynonymous variants with allele frequencies
≥2% were included. Candidate variants were validated
by targeted deep sequencing (Online Supplementary
Methods). A total of 46 somatic mutations were identified
in 34 out of 112 AAV patients (30.4%) with a median
variant allele frequency of 5.2% (Online Supplementary
Table S2). While 25 patients had a single mutation, eight
had two, and one patient had five. The most frequently
mutated genes were DNMT3A (19/46=39,1%), TET2
(7/46=15.2%), and ASXL1 (4/46=8.7%) (Figure 1A).
Among the 46 mutations, 26 were missense, 18 were
truncating and two were splice-site mutations. The most
frequent base change in missense mutations was C > T
(16/30) (Online Supplementary Figure S1).
Compared to previously reported prevalences of CHIP
in unselected control cohorts of similar age and sequenc-
ing technology,3,4,7,8,12-15 the CHIP prevalence in AAV
patients was significantly higher (30.4% vs. 13.5%,
P<0.001) (Figure 1C, Online Supplementary Table S3).
Bearing in mind the different sequencing technologies
used in these studies, we investigated an age- and gen-
der-matched control cohort of 112 healthy individuals,
among whom 22 mutations were found in 20 subjects
(healthy controls vs. AAV patients: 17.9% vs. 30.4%,
P=0.042) (Online Supplementary Table S4, Online
Supplementary Figures S2-S4). Of note, we found a rele-
vant proportion of AAV patients with CHIP aged ≤55
years (6/33=18.2%) (Figure 1B). Follow-up peripheral
blood samples were available for 19 CHIP+ AAV patients.
The median follow-up was 2.3 years (range, 0.3-10.9
years). The mutational burden of serial samples from
these 19 patients at two to four time-points was quanti-
fied by deep sequencing.4,7,16,17 While five patients showed
a relevant increase in clone size, two patients had slightly
decreasing clones and 12 patients showed no change in
clone size over time (Figure 1D, Online Supplementary
Figure S5). Next, we investigated one follow-up sample
from each of 20 CHIP– patients, collected 2 to 10 years
after the initial sample. None of the 20 follow-up samples
showed a new mutation. 
Exploratory statistical analyses were performed to
identify associations between CHIP and clinical parame-
ters (76 patients with granulomatosis with polyangiitis
and 34 with microscopic polyangiitis). CHIP+ patients
were significantly older than CHIP– patients (median 70.5
vs. 63.0 years, respectively, P=0.017). The prevalence of
CHIP was not higher among patients who had received
immunosuppressive treatment prior to sampling (100%
steroids, 90% cyclophosphamide, 20% rituximab, 16%
azathioprine, 13% methotrexate). No differences in
blood counts, red cell distribution width, creatinine lev-
els, comorbidities, the development of malignancies, dis-
ease activity status, and AAV relapse risk were observed
with respect to CHIP status. However, disease manifesta-
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Figure 2. Functional data. Individual data points are depicted in scatterplots and summarized in boxplots. (A) Neutrophil oxidative burst detection using the DHR
assay; depicted is the stimulation index SI = mean channel fluorescence of stimulated versus unstimulated cells, (B, C) Neutrophil membrane expression of
CD177 or PR3 measured on isolated neutrophils by flow cytometry using anti-NB1 or anti-PR3 antibodies, depicted as expression index EI (B) or percentage of
mPR3- and CD177-positive cells (C). EI = (MFIstimulated cells- MFIunstimulated cells) /MFIunstimulated cells. (D) mRNA expression measured in PB leukocytes with qPCR.
(m)PR3: (membrane-)proteinase 3; MPO: myeloperoxidase; RUNX3: Runt-related transcription factor 3; JMJD3: jumonji domain-containing protein 3; DHR: dihy-








tion patterns differed: CHIP+ patients affected by granu-
lomatosis with polyangiitis showed less renal disease
(68.2% vs. 88.5%, P=0.049) and nervous system involve-
ment (0% vs. 19.2%, P=0.028) (Online Supplementary
Tables S5-S8, Online Supplementary Figures S6-S8). 
Next, we aimed to investigate ANCA antigen silencing
and ANCA-induced in vitro activation. To this aim, in vitro
neutrophil stimulation assays using dihydrorhodamine
oxidation with monoclonal antibodies against the ANCA
antigens MPO and PR3 were performed in a subset of
AAV patients and healthy controls (Online Supplementary
Methods) who had tested negative for CHIP. A reduced
activation was observed in CHIP+ compared to CHIP–
AAV patients (anti-MPO: stimulation index: 6.29 vs.
13.01, P=0.057; anti-PR3: stimulation index 7.72 vs.
13.00, P=0.026) (Figure 2A), whereas no difference in
membrane expression index or percentage of positive
cells was observed (Figure 2B, C). In addition, peripheral
blood mRNA levels of PR3, MPO, CD177, RUNX3, and
JMJD3 were measured by quantitative polymerase chain
reaction. CHIP– AAV patients showed increased expres-
sion of MPO and PR3 mRNA compared to levels in
healthy controls (MPO: 1.94 vs. 0.86, P=0.026; PR3: 2.02
vs. 0.58, P=0.057), a difference that was less apparent in
CHIP+ patients. However, CHIP+ AAV patients showed
reduced expression of RUNX3 mRNA compared to the
level in healthy controls (0.28 vs. 0.79, P=0.007) (Figure
2). Due to small numbers of patients, we were not able
to further subdivide CHIP+ AAV patients according to
affected genes or variant allele frequencies and could not
therefore evaluate their potential impact on our findings
(Online Supplementary Table S9). Additionally, significant
differences in neutrophil and lymphocyte counts
between AAV patients and healthy controls might have
affected our results and limit the ability to draw general-
ized conclusions (Online Supplementary Table S10).  
In summary, we detected CHIP in 34 out of 112
patients (30.4%), a significantly higher prevalence than
reported in healthy cohorts and in our age-matched con-
trol group, but comparable to increased frequencies
reported in patients with cancer,12 aplastic anemia18 and
cardiovascular disease.5 While altered inflammatory sig-
naling has been proposed as a mechanism underlying the
association of myelodysplastic syndromes with autoim-
mune diseases/inflammatory conditions,19 a similar
mechanism might link CHIP with such conditions and, in
particular, with AAV. Dysregulated ANCA autoantigen
transcription is commonly observed in AAV and could be
altered by CHIP. Interestingly, CHIP–, but not CHIP+ AAV
patients showed upregulation of autoantigen mRNA
expression that was previously reported.9-11 This rather
surprising finding suggests that the upregulated ANCA
antigen expression is presumably a secondary phenome-
non in AAV, induced by inflammatory signaling which is
defective in CHIP+ cells. In line with this, reduced ANCA-
induced neutrophil activation was observed in CHIP+
patients. Interestingly, we have previously demonstrated
that ANCA-induced production of reactive oxygen
species plays a major role in downregulating inflamma-
some activation by oxidative inhibition of the inflamma-
some-caspase-1-interleukin-1β cascade.20 The diminished
production of reactive oxygen species by CHIP+ neu-
trophils that we found could, therefore, contribute to an
overacting activation of the inflammasome and thereby
affect the pathogenesis of AAV. Clinically, we found
fewer renal and neuronal manifestations in CHIP+
patients, supporting the idea that CHIP functions as a dis-
ease modifier in AAV. 
In longitudinal analysis, more than 25% of patients
showed an increase in clone size over time without any
significant impact of a specific treatment on clone expan-
sion. CHIP frequency was not increased in patients pre-
viously treated with immunosuppressive/cytotoxic
agents and not enriched for mutations involved in DNA
damage response (Online Supplementary Table S11). It
therefore appears unlikely that the high prevalence of
CHIP is merely a consequence of cytotoxic treatment
and, together with the expanding clone sizes, warrants a
closer monitoring of affected AAV patients because of the
known risk of progression to myelodysplastic syndromes
or acute myeloid leukemia.13,15 
Collectively, our data reveal a new association of AAV
with CHIP with potentially disease-modifying effects as
shown for neutrophil activation, autoantigen transcrip-
tion regulation and organ manifestation. We acknowl-
edge that, given the multiple tests, the P-values do not
picture the global type I error. Future studies and func-
tional investigations are now warranted to confirm these
results and decipher the molecular mechanisms. 
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